Transcriptional repressor CTCFL (UniProt Q8NI51; also known as BORIS-like protein, Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CTCF-like protein, CTCF paralog, HMG-1L1, Putative high mobility group protein 1-like 1, Putative high mobility group protein B1-like 1, Zinc finger protein CTCF-T) is encoded by the CTCFL (also known as BORIS, CT27, CTCF-T, dJ579F20.2, HMGB1L1) gene (Gene ID 140690) in human. BORIS is a member of the cancer-testis antigen (CT) family of proteins. BORIS is normally present at high levels in the testis, however it is also aberrantly expressed in various tumors and cancer cell lines. The central DNA-binding region of BORIS is composed of 11 zinc-finger domains similar to CTCF, while the flanking N- and C-terminal regions are distinct between these two paralogs. The appearance of BORIS during germ-line development suggests a role in epigenetic reprogramming in germ cells. BORIS protein is detected in all prostate cell lines and prostate tumors, but it is absent in benign prostatic hyperplasia tissues. Furthermore, increased BORIS protein levels correlate with higher Gleason scores, T-stage and androgen receptor (AR) protein levels in prostate tumors. BORIS is predominantly cytoplasmic in the benign prostatic hyperplasia (BPH) epithelial cell line BPH-1, while BORIS is found to be localized both in the cytoplasm and nucleus among tumorigenic BPH-1 derivatives and established prostate cancer cell lines.
Synonyms: Transcriptional repressor CTCF, BORIS-like protein, Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CTCF-like protein, CTCF paralog, HMG-1L1, Putative high mobility group protein 1-like 1, Putative high mobility group protein B1-li
Application: Western Blotting Analysis: 0.5 µg/mL from a representative lot detected BORIS/CTCFL in 10 µg of NIH/3T3 and LNCaP cell lysates.Western Blotting Analysis: A representative lot detected bacterially expressed Boris N-terminal recombinant fragment, as well as endogenous Boris in mouse embryonic fibroblasts, NIH/3T3, HEK293T, and human prostate cancer cell lines, including PC3, LNCaP, and DU145 (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).Immunocytochemistry Analysis: A representative lot detected a much greater Boris immunoreactivity among human prostate cancer cell lines than the benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 by both flourescent and non-fluorescent immunocytochemistry (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).Chromatin Immunoprecipitation Analysis: A representative lot detected comparable Boris occupany as CTCF at the known CTCF-targeting site (CTS) around PIM-1, while a much weaker association of Boris with another CTS, the Igf2/H19 imprinting control region (H19 ICR) was observed using chromatin preparations from human LNCaP prostate cancer cells (Courtesy of Dr. E. Klenova, University of Essex, UK).Immunohistochemistry Analysis: A representative lot detected Boris immunoreactivity among frozen sections of prostate tumours, but not benign prostatic hyperplasia (BPH) tissues (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).
Other Notes: Concentration: Please refer to lot specific datasheet.